Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy - Tschope, C; Walther, T; Escher, F (FASEB J, 2005)
et al.